What is Arctic Vision?
Arctic Vision operates at the intersection of innovation and clinical excellence, focusing on the development of breakthrough therapies for complex ophthalmic conditions. With a diverse portfolio ranging from pre-clinical research to commercial-stage assets, the company is specifically targeting high-prevalence conditions such as glaucoma and uveitic macular edema. By leveraging a team of seasoned industry professionals, Arctic Vision is effectively bridging the gap between advanced medical research and patient-centric solutions, aiming to establish a dominant footprint in the Asian and global healthcare landscapes. The company's strategic focus on high-barrier-to-entry ophthalmic treatments distinguishes it as a key player in the biotech ecosystem, attracting substantial interest from institutional investors focused on long-term medical innovation.
How much funding has Arctic Vision raised?
Arctic Vision has raised a total of $132M across 2 funding rounds:
Series A
$32M
Series B
$100M
Series A (2020): $32M with participation from Morningside Venture Capital
Series B (2021): $100M led by Octagon Capital, Nan Fung Life Sciences, The Morningside Group, Pivotal bioVenture Partners China, New World Development Group, Tencent, Dr. Adrian Cheng, and Loyal Valley Capital
Key Investors in Arctic Vision
Morningside Venture Capital
A prominent private equity and venture capital firm founded by the Chan family, known for its deep industry expertise and commitment to social responsibility.
Nan Fung Life Sciences
The life sciences investment arm of the Nan Fung Group, a major conglomerate with a core focus on property development and strategic industrial growth in Greater China.
Tencent
A global technology powerhouse that invests in innovation across digital platforms, cloud computing, and healthcare ecosystems to drive cross-industry synergy.
What's next for Arctic Vision?
With the recent infusion of capital, Arctic Vision is well-positioned to scale its commercial operations and advance its late-stage clinical trials. The company's roadmap involves expanding its therapeutic reach and strengthening its intellectual property portfolio to address the growing demand for specialized eye care. As it transitions into a more mature phase of its lifecycle, the firm will likely prioritize regulatory milestones and the commercialization of its lead candidates. This strategic trajectory suggests a focus on sustainable growth, potential international partnerships, and the continued refinement of its R&D capabilities to maintain a competitive edge in the rapidly evolving ophthalmic biotech market.
See full Arctic Vision company page
